PTEN, KDM6A, and ARID1A are not established targets for successful drugs, and their evident loss of function in PDAC does not provide therapeutic strategies that are well-validated in pancreatic cancer patients. This evidence concerns the gene PTEN and familial pancreatic carcinoma.